(Date:12/2/2009)... -- Reportlinker.com announces that a new market r..., Drug Discovery Technologies - A Global Update o.../www.reportlinker.com/p0164246/Drug-Discovery-Tech...tunities.html ,, Drug discovery has become an ...al company,s business strategy. There are a number...
(Date:12/2/2009)...FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics"...ced today that in connection with its previously a...cised in full their over-allotment option and purc...mprised of one common share and 0.4 of a common sh...S$3.00 per unit. Each whole common share purchase ...
(Date:12/2/2009)...ber 2 Gamida Cell announced today,...imal study) safety and,efficacy of a gene therapy ...ll Medical College and Gamida Cell. The product ma...s Cooley,s Anemia. , Gamida Cell is devel...,populations of stem/progenitor cells. The company...
(Date:12/2/2009)...stCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; T...al company focused on endocrine therapy and oncolo...ministration (FDA) has granted Fast Track designat...ompound, perifosine (KRX-0401), for the treatment ...pharmaceuticals, Inc. ("Keryx") ( KERX), is AEtern...
Breaking Biology Technology:Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3...demonstrate ANAVEX 1-41 has significant ...NEVA, Nov. 28 /PRNewswire-FirstCall/ - Anavex Life...d to announce promising developments with,ANAVEX 1...er,s disease. In,recent pre-clinical animal studie...mages and destroys cells and is believed to be a p...
...efs concerning the,economic and business growth in...ip:, SRI Launches First Major Project to Improve ... a five-year, $36.5 million contract,to develop a ...ate advanced,sensing and situation awareness techn...States. The contract was awarded to SRI by the U.S...
...esults of a,study on children confirmed the effica...ation product, which is due to receive German mark...ic study, VO52.06, which was carried out on 280,pa...rgic,rhino-conjunctivitis, fully met the main eval...significant reduction in symptoms, comparable,to t...
Other Biology Technology:Anavex advances drug candidate for treatment of Alzheimer's disease 2Anavex advances drug candidate for treatment of Alzheimer's disease 3Anavex advances drug candidate for treatment of Alzheimer's disease 4Anavex advances drug candidate for treatment of Alzheimer's disease 5Highlights of Economic and Business Growth in the Tampa Bay Region 2Highlights of Economic and Business Growth in the Tampa Bay Region 3Highlights of Economic and Business Growth in the Tampa Bay Region 4STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study 2PCNA Immunohistochemistry Assay Kit from Invitrogen
Varian Cary 6000i Spectrophotometer from Varian, Inc.
Gln(Trt) Peptide Synthesis Column from Applied Biosystems
E. coli Expression System with Gateway Technology from Invitrogen
Biology Products: